Hemab Therapeutics (NASDAQ:COAG) Trading Up 8.4% on Insider Buying Activity

Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG) was up 8.4% on Thursday following insider buying activity. The stock traded as high as $28.68 and last traded at $28.67. Approximately 40,831 shares traded hands during trading, a decline of 81% from the average daily volume of 215,140 shares. The stock had previously closed at $26.45.

Specifically, major shareholder Ra Capital Management, L.P. acquired 61,523 shares of the stock in a transaction that occurred on Tuesday, June 16th. The shares were purchased at an average cost of $24.98 per share, for a total transaction of $1,536,844.54. Following the transaction, the insider directly owned 6,444,637 shares in the company, valued at approximately $160,987,032.26. This represents a 0.96% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link. Also, major shareholder Ra Capital Management, L.P. acquired 6,146 shares of the stock in a transaction that occurred on Monday, June 15th. The stock was purchased at an average price of $24.89 per share, for a total transaction of $152,973.94. Following the completion of the transaction, the insider owned 6,383,114 shares in the company, valued at $158,875,707.46. The trade was a 0.10% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure.

Wall Street Analysts Forecast Growth

COAG has been the topic of several research analyst reports. HC Wainwright initiated coverage on shares of Hemab Therapeutics in a research report on Wednesday. They set a “buy” rating and a $40.00 target price on the stock. Wedbush initiated coverage on shares of Hemab Therapeutics in a research report on Tuesday, May 26th. They set an “outperform” rating and a $42.00 target price on the stock. The Goldman Sachs Group assumed coverage on shares of Hemab Therapeutics in a research report on Tuesday, May 26th. They set a “buy” rating and a $36.00 target price on the stock. Jefferies Financial Group assumed coverage on Hemab Therapeutics in a research note on Tuesday, May 26th. They set a “buy” rating and a $39.00 price target for the company. Finally, Wall Street Zen raised Hemab Therapeutics to a “hold” rating in a research note on Saturday, May 9th. Five research analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $41.40.

Hemab Therapeutics Trading Up 7.2%

Hemab Therapeutics (NASDAQ:COAG) last announced its earnings results on Thursday, May 21st. The company reported ($23.98) earnings per share for the quarter.

About Hemab Therapeutics

Hemab Therapeutics is a clinical-stage biotechnology company focused on developing novel therapies for people with serious bleeding and thrombotic disorders. The company’s research is centered on treatments designed to address diseases of the blood and coagulation system, with the goal of improving outcomes for patients who may not be adequately served by existing options.

Hemab’s pipeline includes drug candidates aimed at rare hematologic conditions, including factor XI-related approaches and other programs in inherited bleeding disorders.